Your Gateway to America's Market and Global Opportunities

Your Company Could Be Here

Global Exposure. Real Business Results.

Advertise with ATN
Join ATN

Top Losers: The Biggest Stock Declines in North America and Why

Top Losers: The Biggest Stock Declines in North America and Why

ATN BREAKING NEWS |

Top Losers: The Biggest Stock Declines in North America and Why

October 8, 2026 | ATN Trade & Finance

Thursday's session was defined by a sharp, concentrated selloff in artificial intelligence and semiconductor stocks, triggered by a single news report that called the entire AI spending narrative into question. Here are the biggest decliners and what drove each one lower.

1. Arm Holdings (ARM) — Down More Than 6%

Arm led the semiconductor sector lower after a Financial Times report revealed that OpenAI's annualized revenue had come in significantly below earlier projections. Because Arm's licensing model is directly tied to AI chip demand — its processor architectures appear in virtually every major AI inference chip — any credible downward revision to AI spending plans lands squarely on Arm's revenue outlook. The stock had already been under pressure from SoftBank's expanded margin loan tied to Arm shares (raised to approximately $25 billion in late September), which creates technical overhang whenever the stock weakens.

2. Intel (INTC) and Marvell Technology (MRVL) — Each Down More Than 6%

Intel and Marvell fell in lockstep with Arm, each dropping more than 6% at session lows. For Marvell, the hit is particularly direct: the company has positioned its custom AI ASIC business as its core growth driver, and slower-than-expected OpenAI scaling would reduce demand for exactly those chips. Intel's decline reflects broader semiconductor contagion — the stock has limited direct AI revenue today, but trades closely with the sector's sentiment.

3. Micron Technology (MU) — Down More Than 5%

Micron, the bellwether for AI memory demand, fell more than 5% on the session. High-bandwidth memory (HBM) is a critical component in AI training and inference hardware, and Micron has been one of the key beneficiaries of hyperscaler AI capital expenditure. Any deceleration in AI build-out translates directly into softer HBM order forecasts, hitting Micron harder than most chip names. The Philadelphia Semiconductor Index (SOX) fell as much as 4% intraday as the sector-wide ripple spread.

4. Eli Lilly (LLY) — Down Approximately 3.1%

Eli Lilly's decline was driven by a separate set of factors. An institutional endowment disclosed plans to sell a large block of shares, adding technical selling pressure. Beneath that, analysts flagged continued net price erosion in GLP-1 drugs: expanded commercial and government insurance coverage for Mounjaro and Zepbound has helped volume but is compressing realized prices. Competition from Novo Nordisk in both injectable and oral weight-loss drugs also remains a persistent overhang. The stock fell despite no negative company-specific news on the day — a sign that after Lilly's extraordinary 2025–2026 run, valuation sensitivity is now a real consideration.

5. Starbucks (SBUX) — Down Approximately 4–5% Intraday

Starbucks was an unusual loser on Thursday, falling on a report that it had previously explored a takeover of Chipotle Mexican Grill. The news hit Starbucks for two reasons: it raised questions about strategic focus at a time when the company is still executing a turnaround under CEO Brian Niccol, and it prompted speculation about how much capital any such deal would have required. Starbucks shares recovered somewhat through the afternoon but remained lower on the session. Chipotle, by contrast, surged more than 7% on the same story.

What this means for traders and investors: The AI-linked selloff on Thursday is different from a broad market pullback — it is a repricing event within a specific narrative. Arm, Marvell, and Micron are all pricing in a world where AI capital expenditure remains exceptional; any credible evidence that the ramp is slower than assumed hits these names disproportionately hard. For Eli Lilly, the institutional selling is noise, but the pricing pressure on GLP-1 drugs is a structural issue worth watching across the healthcare sector. For Starbucks, the Chipotle story is an unwelcome distraction from the core turnaround story — watch Q4 same-store sales for the real signal on whether Niccol's strategy is working.

Sources:

Leave a comment